Exchange: OTC Sector: Healthcare Industry: Diagnostics & Research
Current Signal: BUY (auto-tracking)
0.32% $0.604
America/New_York / 3 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 10.67 mill |
EPS: | -0.180 |
P/E: | -3.36 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 17.67 mill |
Avg Daily Volume: | 1.603 mill |
RATING 2024-05-03 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.36 | sector: PE 29.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.32x |
Company: PE -3.36 | industry: PE 10.51 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.514 - 0.694 ( +/- 14.90%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-19 | Wong Yee Meng | Buy | 0 | |
2023-07-19 | Yap Chee Keong | Buy | 0 | |
2023-07-19 | Yew Chak Hua | Buy | 0 | |
2023-07-19 | Lin Chai Ping | Buy | 0 | |
2023-07-19 | Teoh Boon Teong | Buy | 0 |
INSIDER POWER |
---|
0.00 |
Last 2 transactions |
Buy: 0 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.604 (0.32% ) |
Volume | 0.118 mill |
Avg. Vol. | 1.603 mill |
% of Avg. Vol | 7.37 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 13 - 11:15 | buy | $1.900 | N/A | Active |
---|
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.